相似文献
1
Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes.
Diabet Med. 2008 Sep;25(9):1129-31. doi: 10.1111/j.1464-5491.2008.02484.x.
2
A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus.
Clin Ther. 2009 Nov;31(11):2472-88. doi: 10.1016/j.clinthera.2009.11.034.
3
Liraglutide: a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes mellitus.
Am J Health Syst Pharm. 2010 Aug 15;67(16):1326-36. doi: 10.2146/ajhp090230.
4
Liraglutide for type 2 diabetes mellitus.
Expert Opin Biol Ther. 2011 Jul;11(7):951-9. doi: 10.1517/14712598.2011.583641. Epub 2011 May 12.
5
Liraglutide: a once-daily GLP-1 analogue for the treatment of type 2 diabetes mellitus.
Expert Opin Investig Drugs. 2007 Feb;16(2):231-7. doi: 10.1517/13543784.16.2.231.
6
Population pharmacokinetics of liraglutide, a once-daily human glucagon-like peptide-1 analog, in healthy volunteers and subjects with type 2 diabetes, and comparison to twice-daily exenatide.
J Clin Pharmacol. 2010 Aug;50(8):886-94. doi: 10.1177/0091270009354996. Epub 2010 Feb 4.
7
Retrospective real-world adherence in patients with type 2 diabetes initiating once-daily liraglutide 1.8 mg or twice-daily exenatide 10 μg.
Clin Ther. 2013 Jun;35(6):795-807. doi: 10.1016/j.clinthera.2013.03.021. Epub 2013 May 1.
8
One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes.
Diabetes. 2004 May;53(5):1187-94. doi: 10.2337/diabetes.53.5.1187.
9
Next-generation GLP-1 therapy: an introduction to liraglutide.
Postgrad Med. 2011 Sep;123(5):239-47. doi: 10.3810/pgm.2011.09.2480.
10
Liraglutide: from clinical trials to clinical practice.
Diabetes Obes Metab. 2012 Apr;14 Suppl 2:33-40. doi: 10.1111/j.1463-1326.2012.01576.x.
引用本文的文献
1
Effect of the GLP-1 receptor agonist exenatide on pro-inflammatory and metabolic biomarkers in individuals with alcohol use disorder: Post hoc results from a randomized, double-blinded, placebo-controlled clinical trial.
Alcohol Clin Exp Res (Hoboken). 2025 Aug;49(8):1659-1666. doi: 10.1111/acer.70110. Epub 2025 Jul 9.
2
Semaglutide: a key medication for managing cardiovascular-kidney-metabolic syndrome.
Future Cardiol. 2025 Jul;21(9):663-683. doi: 10.1080/14796678.2025.2511412. Epub 2025 Jun 3.
3
Safety and efficacy of glucagon-like peptide-1 receptor agonists in patients with obstructive sleep apnea: a systematic review and meta-analysis of randomized controlled trials.
Eur Clin Respir J. 2025 Mar 24;12(1):2484048. doi: 10.1080/20018525.2025.2484048. eCollection 2025.
4
Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists: Exploring Their Impact on Diabetes, Obesity, and Cardiovascular Health Through a Comprehensive Literature Review.
Cureus. 2024 Sep 1;16(9):e68390. doi: 10.7759/cureus.68390. eCollection 2024 Sep.
5
Effects of Semaglutide and Empagliflozin on Inflammatory Markers in Patients with Type 2 Diabetes.
Int J Mol Sci. 2023 Mar 16;24(6):5714. doi: 10.3390/ijms24065714.
6
Effect of Sitagliptin Glibenclamide on Glycemic Markers, Lipid Profile Inflammatory and Oxidative Stress Factors in Type 2 Diabetes Patients: a Double-Blinded Randomized Controlled Trial.
Maedica (Bucur). 2022 Dec;17(4):762-770. doi: 10.26574/maedica.2022.17.4.762.
7
Comparative effects of weight loss and incretin-based therapies on vascular endothelial function, fibrinolysis and inflammation in individuals with obesity and prediabetes: A randomized controlled trial.
Diabetes Obes Metab. 2023 Feb;25(2):570-580. doi: 10.1111/dom.14903. Epub 2022 Nov 10.
8
DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits.
Mil Med Res. 2022 Aug 20;9(1):45. doi: 10.1186/s40779-022-00410-2.
9
Glucagon-like Peptide-1 Receptor Agonists in the Management of Type 2 Diabetes Mellitus and Obesity: The Impact of Pharmacological Properties and Genetic Factors.
Int J Mol Sci. 2022 Mar 22;23(7):3451. doi: 10.3390/ijms23073451.
10
Glucagon-Like Peptide 1 Receptor Agonists - Potential Game Changers in the Treatment of Glaucoma?
Front Neurosci. 2022 Feb 21;16:824054. doi: 10.3389/fnins.2022.824054. eCollection 2022.
本文引用的文献
1
Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus.
Diabet Med. 2008 Feb;25(2):152-6. doi: 10.1111/j.1464-5491.2007.02333.x. Epub 2008 Jan 14.
2
Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes.
Diabetes Care. 2007 Jun;30(6):1608-10. doi: 10.2337/dc06-2593. Epub 2007 Mar 19.
3
The metabolic syndrome: inflammation, diabetes mellitus, and cardiovascular disease.
Am J Cardiol. 2006 Jan 16;97(2A):3A-11A. doi: 10.1016/j.amjcard.2005.11.010. Epub 2005 Dec 5.
4
Initial experience with GLP-1 treatment on metabolic control and myocardial function in patients with type 2 diabetes mellitus and heart failure.
Diab Vasc Dis Res. 2004 May;1(1):40-3. doi: 10.3132/dvdr.2004.005.
5
Plasma N-terminal pro-brain natriuretic peptide as a major risk marker for cardiovascular disease in patients with type 2 diabetes and microalbuminuria.
Diabetologia. 2005 Jan;48(1):156-63. doi: 10.1007/s00125-004-1607-0. Epub 2004 Dec 24.
6
Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease.
Am J Physiol Endocrinol Metab. 2004 Dec;287(6):E1209-15. doi: 10.1152/ajpendo.00237.2004. Epub 2004 Sep 7.
Zotero 插件